M
ME NEWS
10 Jun 2025, 16:39
Axsome Shareholders Approve Key Proposals at 2025 Annual Meeting
NEW YORK – June 9, 2025 – Axsome Therapeutics, Inc. (Nasdaq: AXSM) announced the results of its 2025 Annual Meeting of Stockholders held on June 6. Approximately 84% of eligible shares were represented.
Meeting Highlights:
Roger A. Jeffs, Ph.D. was elected as Class I director to serve until the 2028 annual meeting.
Stockholders approved the 2025 Long-Term Incentive Plan.
Deloitte & Touche LLP was ratified as the Company’s independent auditor for fiscal year 2025.
A non-binding vote approved the compensation of the Company’s named executive officers.
All proposals received majority support, reinforcing shareholder confidence in Axsome’s leadership and strategic direction.
NEW YORK – June 9, 2025 – Axsome Therapeutics, Inc. (Nasdaq: AXSM) announced the results of its 2025 Annual Meeting of Stockholders held on June 6. Approximately 84% of eligible shares were represented.
Meeting Highlights:
Roger A. Jeffs, Ph.D. was elected as Class I director to serve until the 2028 annual meeting.
Stockholders approved the 2025 Long-Term Incentive Plan.
Deloitte & Touche LLP was ratified as the Company’s independent auditor for fiscal year 2025.
A non-binding vote approved the compensation of the Company’s named executive officers.
All proposals received majority support, reinforcing shareholder confidence in Axsome’s leadership and strategic direction.
